Be part of the knowledge

Medical News

buffalo.edu
12/02/2022
Medical News
New Tool Twice as Accurate at Predicting Antibody Resistance Among U.S. Childre…
Read more
prnewswire.com
12/02/2022
Medical News
COVID-19 Patients Show Liver Injury Months After Infection
Read more
brown.edu
12/02/2022
Medical News
Postpartum Visits Declined During COVID-19, Especially Among Black, Young & Uni…
Read more

See more news

- Marlies Ostermann, MD
  Peer
- Rinaldo Bellomo, MBBS, MD, FRACP
  Peer
2
Nephrology
The Role of Hemodynamics for AKI and Maintaining Hemodynamic Stability in KRT Patients
The Role of Hemodynamics for AKI and Maintaining Hemodynamic Stability in KRT Patients
The Role of Hemodynamics for AKI and Maintaining Hemodynamic Stability in KRT P…
- Marlies Ostermann, MD
  Peer
- Javier Neyra, MD, MSCS
  Peer
2
Nephrology
Best Practices in Fluid Management During CKRT
Best Practices in Fluid Management During CKRT
Best Practices in Fluid Management During CKRT
- Robert J. Mentz, MD, FHFSA, FACC, FAHA
  Peer
- Peter van der Meer, MD, PhD
  Peer
4
CME/CE
What Are We Missing? Iron Deficiency in Heart Failure
What Are We Missing? Iron Deficiency in Heart Failure
0.25 credits
What Are We Missing? Iron Deficiency in Heart Failure
0.25 credits
- Piotr Ponikowski, MD, PhD, FESC, FHFA
  Peer
- Adrian F. Hernandez, MD, MHS
  Peer
- Professor Andrew Sindone
  Peer
1
CME/CE
What You Should Know When Addressing GDMT For ID in Heart Failure
What You Should Know When Addressing GDMT For ID in Heart Failure
0.25 credits
What You Should Know When Addressing GDMT For ID in Heart Failure
0.25 credits
- Charles P. Vega, MD
  Peer
- Rajeev Raghavan, MD, M.Ed, FASN
  Peer
2
CME/CE
Anemia in Chronic Kidney Disease: Improved Patient Outcomes Needed STAT!
Anemia in Chronic Kidney Disease: Improved Patient Outcomes Needed STAT!
0.50 credits
Anemia in Chronic Kidney Disease: Improved Patient Outcomes Needed STAT!
0.50 credits
- Suzanne J. Baron, MD
  Peer
- Jonathan A. Bradlow, MD, FACC
  Peer
- Kendra J. Grubb, MD
  Peer
3
CME/CE
Experts Discuss Longevity and Durability with TAVR
Experts Discuss Longevity and Durability with TAVR
0.25 credits
Experts Discuss Longevity and Durability with TAVR
0.25 credits

Featured

- Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
  Peer
- Javier Morales, MD, FACP, FACE
  Peer
- Angela Yee-Moon Wang, MD, FACP, FACE
  Peer
12
CME/CE
A New Option for Cardiorenal Protection for Patients with CKD in T2D
A New Option for Cardiorenal Protection for Patients with CKD in T2D
0.25 credits
A New Option for Cardiorenal Protection for Patients with CKD in T2D
0.25 credits
- Pam R. Taub, MD, FACC, FASPC
  Peer
- George L. Bakris, MD
  Peer
- Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
  Peer
5
CME/CE
Reducing Morbidity and Mortality in Patients with CKD in T2D: New Late-Breaking Data
Reducing Morbidity and Mortality in Patients with CKD in T2D: New Late-Breaking Data
0.50 credits
Reducing Morbidity and Mortality in Patients with CKD in T2D: New Late-Breaking…
0.50 credits
- Christie M. Ballantyne, MD
  Peer
- Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP
  Peer
- Joseph Saseen, PharmD, BCPS, BCACP, CLS
  Peer
- Karol Watson, MD, PhD
  Peer
20
CME/CE Broadcast Replay
CME/CE Broadcast Replay
Adopting the New Therapeutic “Lineup” to Manage ASCVD - Central
Adopting the New Therapeutic “Lineup” to Manage ASCVD - Central
3.50 credits
Adopting the New Therapeutic “Lineup” to Manage ASCVD - Central
3.50 credits
- Ahmad Masri, MD, MS
  Peer
- Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
  Peer
9
CME/CE
Emerging Therapies in Hypertrophic Cardiomyopathy: The Potential Role of Cardiac Myosin Inhibition
Emerging Therapies in Hypertrophic Cardiomyopathy: The Potential Role of Cardiac Myosin Inhibition
0.25 credits
Emerging Therapies in Hypertrophic Cardiomyopathy: The Potential Role of Cardia…
0.25 credits